Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methicillin acyl-serine is an experimental small molecule derivative related to methicillin. It is a synthetic compound with the molecular formula C20H25N3O9S and a molecular weight of approximately 483.5 g/mol[1][3]. The structure features a thiazolidine ring and an acylated serine moiety[10]. While detailed pharmacological data are not available for this specific compound in clinical use or trials[1], it is likely designed as a mechanistic probe or intermediate for studying beta-lactam antibiotics such as methicillin. Methicillin itself acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), particularly transpeptidases involved in peptidoglycan cross-linking[4][7]. The "acyl-serine" motif suggests this molecule may mimic the covalent intermediate formed between beta-lactams and serine residues in PBPs or beta-lactamase enzymes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methicillin acyl-serine.